Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial

Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial
Zenith Epigenetics has started a Phase 1b clinical trial to assess the safety and tolerability of its orally administered BET inhibitor ZEN-3694 in combination with Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after first-line androgen-deprivation therapy. Current standard of care treatment for prostate cancer patients consists of androgen deprivation therapies such as Xtandi, which blocks the androgen receptor, or Zitiga (abiraterone), which impairs the synthesis of androgens. Although most patients respond to these castration therapies, nearly all patients eventually become resistant to them. Castration-resistant prostate cancer patients have no effective therapies to treat their disease. But recently, pre-clinical studies have suggested that BET inhibitors, which disrupt DNA remodeling and gene expression, leading to the inhibition of cancer cell proliferation, show promise in mCRPC patients. The open-label, single-arm study (NCT02711956) will assess the safety and tolerability of the BET inhibitor ZEN-3694 in combination with Xtandi in mCRPC patients. It will encompass a first dose-escalation phase to assess the optimal ZEN-3694 dose and dose-limiting toxicities, followed by an expansion phase assessing the safety of ZEN-3694 at the selected dose. "We are excited to reach this second important milestone for Zenith Epigenetics and the development of ZEN-3694," Donald McCaffrey, president and CEO of Zenith, said in a
Subscribe or to access all post and page content.